Biyong Ren

机构：Chongqing University, Chongqing Three Gorges Central Hospital, Chongqing Three Gorges University

发表论文 34 篇 · 总被引 250 次 · h-index 8

代表论文

• Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial (2019 · Clinical Cancer Research · 被引 74)
• Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer (2019 · Translational Lung Cancer Research · 被引 36)
• Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial (2020 · Neuro-Oncology · 被引 31)
• Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin (2022 · 癌症：英文版 · 被引 17)
• Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report (2021 · Frontiers in Oncology · 被引 15)
• Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial (2020 · Annals of Translational Medicine · 被引 13)